- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01837199
MTZ Plus AMX in the Treatment of Smokers and Non-smokers
Clinical and Microbiological Effects of Adjunctive Metronidazole Plus Amoxicillin in the Treatment of Generalized Chronic Periodontitis: Smokers Versus Non-Smokers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sample size calculation:
This study is designed to compare the clinical and microbiological effects of the treatment of smoker and non-smoker subjects with SRP+MTZ+AMX. The ideal sample size to assure adequate power for this clinical trial was calculated considering differences of at least 1mm between groups for clinical attachment level (CAL) in initially deep periodontal sites (PD ≥ 7 mm). It was also determined that the standard deviation of CAL change at deep sites would be 1.0 mm based on our earlier studies of smokers and non-smokers receiving SRP combined with MTZ+AMX. Based on these calculations, it was defined that 26 subjects per group would be necessary to provide an 85% power with an α of 0.01. Considering an attrition of about 20%, it was established that at least 32 subjects should be included in each treatment group.
Experimental design and treatment protocol:
In this cohort clinical trial, subjects will be assigned according to their smoking status, into smoker and non-smoker groups. All subjects will receive SRP combined with systemic MTZ (400 mg) and AMX (500 mg). Both antibiotics will be administered T.I.D. for 14 days. Before the study begins, all subjects will receive full-mouth supragingival scaling and instruction on proper home-care techniques. They will receive the same dentifrice to use during the study period (Colgate Total). All subjects will receive full-mouth SRP performed under local anesthesia in four to six appointments lasting approximately 1h each. Treatment of the entire oral cavity will be done in 14 days. SRP will be performed by one trained periodontist using manual instruments. The antibiotic therapies will start immediately after the first session of mechanical instrumentation. The University Pharmacy will prepare the antibiotic pills and send them to the study coordinator, who will mark the code number of each subject on a set of two packs and give them to the examiner. All subjects will receive clinical and microbiological monitoring at baseline and at 3, 6 and 12 months post-therapy.
Clinical monitoring:
One calibrated examiner will perform clinical monitoring and the treatment will carried out by another clinician. Thus, the examiner and the clinician will be masked as to the nature of the treatment groups. Visible plaque (presence or absence), gingival bleeding (presence or absence), bleeding on probing (BOP; presence or absence), suppuration (presence or absence), PD (mm) and clinical attachment level (CAL, mm) will be measured at six sites per tooth (mesiobuccal, buccal, distobuccal, distolingual, lingual and mesiolingual) in all teeth, excluding third molars. The PD and CAL measurements will be recorded to the nearest millimeter using a North Carolina periodontal probe.
Microbiological Monitoring:
Subgingival plaque samples will be collected at baseline and at 3, 6 and 12 months post-SRP from nine non-contiguous interproximal sites per subject. The select sites will be randomized in different quadrants and subset according to baseline PD, three samples in each of the following categories: shallow (PD<3 mm), intermediate (PD 4-6 mm) and deep (PD>7 mm). After the clinical parameters have been recorded, the supragingival plaque will be removed and the subgingival samples will be taken with individual sterile curettes (Gracey #11-12) and immediately placed in separate Eppendorf tubes containing 0.15 ml of buffer (TE). One hundred microliters of 0.5 M sodium hydroxide (NaOH) will be added to each tube and the samples will be dispersed using a vortex mixer. The samples will be analyzed by Checkerboard DNA-DNA hybridization.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
São Paulo/ SP
-
Guarulhos, São Paulo/ SP, Brazil, 07023-070
- University of Guarulhos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic periodontitis (AAP 1999);
- ≥35 years of age;
- Presence of at least 15 teeth;
- Minimum of 6 teeth with at least one site each with PD and clinical attachment level (CAL) ≥5 mm;
- At least 30% of the sites with PD and CAL ≥4 mm and bleeding on probing (BOP).
- Smokers: had smoked at least 10 cigarettes per day for a minimum of 5 years;
- Non-smokers: had never smoked.
Exclusion Criteria:
- Previous subgingival periodontal therapy;
- Pregnancy;
- Nursing;
- Systemic diseases that could affect the progression of periodontal disease (e.g. diabetes, osteoporosis);
- Long-term administration of anti - inflammatory medications;
- Need for antibiotic pre-medication for routine dental therapy;
- Continuous use of mouthrinses containing antimicrobials;
- Antibiotic therapy in the previous 6 months
- Allergy to MTZ or AMX.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Smoking
Metronidazole plus Amoxicillin
|
All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg).
Both antibiotics were administered T.I.D. for 14 days.
Other Names:
|
EXPERIMENTAL: Non-Smoking
Metronidazole plus Amoxicillin
|
All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg).
Both antibiotics were administered T.I.D. for 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean clinical attachment level change post- scaling and root planing in sites with initial probing depth ≥ 7 mm
Time Frame: At 3, 6 and 12 months post-therapy.
|
At 3, 6 and 12 months post-therapy.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with low, moderate and high risk for disease progression.
Time Frame: At 3, 6 and 12 months post-therapy
|
At 3, 6 and 12 months post-therapy
|
Mean full-mouth clinical attachment level.
Time Frame: Baseline and at 3, 6 and 12 months post-therapy
|
Baseline and at 3, 6 and 12 months post-therapy
|
Mean full-mouth probing depth.
Time Frame: Baseline and at 3, 6 and 12 months post-therapy.
|
Baseline and at 3, 6 and 12 months post-therapy.
|
Mean clinical attachment level change post-scaling and root planing in sites with initial probing depth between 4-6 mm
Time Frame: At 3, 6 and 12 months post-therapy
|
At 3, 6 and 12 months post-therapy
|
Mean probing depth reduction post-scaling and root planing in sites with initial probing depth between 4-6 mm
Time Frame: At 3, 6 and 12 months post-therapy.
|
At 3, 6 and 12 months post-therapy.
|
Mean probing depth reduction post-scaling and root planing in sites with initial probing depth ≥ 7 mm
Time Frame: At 3, 6 and 12 months post-therapy.
|
At 3, 6 and 12 months post-therapy.
|
Mean changes in levels of the 40 bacterial species evaluated by Checherboard DNA-DNA hybridization
Time Frame: At 3, 6 and 12 months post-therapy.
|
At 3, 6 and 12 months post-therapy.
|
Mean changes in proportions of the 40 bacterial species evaluated by Checherboard DNA-DNA hybridization
Time Frame: At 3, 6 and 12 months post-therapy
|
At 3, 6 and 12 months post-therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marcelo Faveri, DDS, PhD., University of Guarulhos
- Principal Investigator: Magda Feres, DDS, PhD., University of Guarulhos
- Principal Investigator: Luciene C Figueiredo, DDS, PhD., University of Guarulhos
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SISNEP/726
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
Clinical Trials on Metronidazole plus Amoxicillin
-
University of ChileColgate PalmoliveCompletedChronic Periodontitis | Clinical and Microbiological EffectsChile
-
Federal University of Minas GeraisConselho Nacional de Desenvolvimento Científico e TecnológicoEnrolling by invitation
-
Mohammed V Souissi UniversityCompleted
-
University of Geneva, SwitzerlandCompletedChronic PeriodontitisSwitzerland
-
University of Campinas, BrazilRecruitingPeriodontal Diseases | Microbial Colonization | Periodontal InflammationBrazil
-
University of Campinas, BrazilCompletedGeneralized Aggressive Periodontitis
-
University Hospital MuensterCompleted
-
Taibah UniversityCompletedChronic Periodontitis, Generalized
-
The Forsyth InstituteBoston University; Göteborg UniversityCompleted
-
Dow University of Health SciencesCompleted